BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 3792668)

  • 1. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome.
    Bardram L; Thomsen P; Stadil F
    Digestion; 1986; 35 Suppl 1():116-22. PubMed ID: 3792668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells.
    Maton PN; Lack EE; Collen MJ; Cornelius MJ; David E; Gardner JD; Jensen RT
    Gastroenterology; 1990 Oct; 99(4):943-50. PubMed ID: 1697548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
    Hage E; Hendel L; Gustafsen J; Hendel J
    Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome.
    Feurle GE
    Gut; 1994 Feb; 35(2):275-7. PubMed ID: 8307483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients.
    Delle Fave G; Marignani M; Corleto VD; Angeletti S; D'Ambra G; Ferraro G; D'Adda T; Azzoni C; Jensen RT; Annibale B; Bordi C
    Dig Liver Dis; 2002 Apr; 34(4):270-8. PubMed ID: 12038811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
    Hirschowitz BI; Haber MM
    Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger-Ellison syndrome during omeprazole treatment.
    Caruana P; Azzoni C; Bertelé A; Annibale B; Franzé A; Delle Fave G; Bordi C
    Histopathology; 1992 Oct; 21(4):359-63. PubMed ID: 1398539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enterochromaffin-like (ECL) cells and their growths: relationships to gastrin, reduced acid secretion and gastritis.
    Solcia E; Rindi G; Silini E; Villani L
    Baillieres Clin Gastroenterol; 1993 Mar; 7(1):149-65. PubMed ID: 7682874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome.
    Aprile MR; Azzoni C; Gibril F; Jensen RT; Bordi C
    Hum Pathol; 2000 Feb; 31(2):140-8. PubMed ID: 10685627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
    Hirschowitz BI; Mohnen J; Shaw S
    Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth.
    Creutzfeldt W; Lamberts R
    Digestion; 1992; 51 Suppl 1():76-81. PubMed ID: 1397748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypergastrinemia and gastric enterochromaffin-like cells.
    Bordi C; D'Adda T; Azzoni C; Pilato FP; Caruana P
    Am J Surg Pathol; 1995; 19 Suppl 1():S8-19. PubMed ID: 7762739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.
    Maton PN; Vinayek R; Frucht H; McArthur KA; Miller LS; Saeed ZA; Gardner JD; Jensen RT
    Gastroenterology; 1989 Oct; 97(4):827-36. PubMed ID: 2777040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antisecretory drugs, hypergastrinemia and hyperplasia of enterochromaffin-like cells (ECL)].
    Andriulli A; Mangia A; Lawson F
    Minerva Gastroenterol Dietol; 1991; 37(3):135-40. PubMed ID: 1686409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment.
    Lehy T; Mignon M; Cadiot G; Elouaer-Blanc L; Ruszniewski P; Lewin MJ; Bonfils S
    Gastroenterology; 1989 Apr; 96(4):1029-40. PubMed ID: 2925050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histomorphological characteristics of gastric mucosa in patients with Zollinger-Ellison syndrome or autoimmune gastric atrophy: role of gastrin and atrophying gastritis.
    Lehy T; Roucayrol AM; Mignon M
    Microsc Res Tech; 2000 Mar; 48(6):327-38. PubMed ID: 10738314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxyntic mucosa histology in omeprazole-treated patients suffering from duodenal ulcer or Zollinger-Ellison syndrome.
    Helander HF
    Digestion; 1986; 35 Suppl 1():123-9. PubMed ID: 3792669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereologic investigations of human gastric mucosa. II. Oxyntic mucosa from patients with Zollinger-Ellison syndrome.
    Helander HF; Rutgersson K; Helander KG; Pisegna JP; Gardner JD; Jensen RT; Maton PN
    Scand J Gastroenterol; 1992 Oct; 27(10):875-83. PubMed ID: 1439541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Present experiences with omeprazole in the Zollinger-Ellison syndrome.
    Lamers CB
    Scand J Gastroenterol Suppl; 1986; 118():123-8. PubMed ID: 3460167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.